However, Subramaniam et al. proved that a TNF-α inhibitor, infliximab, can inhibit the activation of NF-κB, reduce proteolysis and sarcolysis, and accelerate muscle formation to reverse sarcopenia [32]. This evidence concerns the gene NFKB1 and sarcopenia.